BlinkLab Limited (ASX: BB1)

Australia · spotlight · May 26, 2026

BlinkLab Limited (ASX: BB1)

Speculative Buy: BlinkLab’s AI smartphone neurodiagnostics platform reports strong pilot results (83.7% sensitivity, 84.7% specificity) and has an active FDA 510(k) pivotal program with a defined Q4 2026 submission and Q1 2027 clearance timeline, plus Morocco national rollout and ADHD/CE-MDR optionality that could materially de-risk value; however, clinical, regulatory, commercialisation, reimbursement and dilution risks remain.

BlinkLab Limited (ASX: BB1)

Investment thesis: BlinkLab’s smartphone-based AI neurodiagnostics platform has delivered strong pilot performance and a clearly defined FDA 510(k) pivotal pathway, creating an asymmetric risk/reward into a near-dated regulatory catalyst. We initiate coverage as a Speculative Buy given the potential to scale low‑friction diagnostic tools across autism and ADHD despite residual clinical, regulatory and commercial risks.

  • Robust pilot data: Reported 83.7% sensitivity and 84.7% specificity across a 485‑child US pilot, comfortably above the company’s stated FDA pre‑submission benchmarks.

  • Near‑term FDA catalyst: Active double‑blind, multicentre Dx1 pivotal study with Q4 2026 target for FDA submission and an expected Q1 2027 clearance timeline.

  • Large real‑world rollout: Morocco national screening program (up to 3,000 centres / 600,000 children annually) provides substantial real‑world data generation and commercial validation opportunity.

  • Platform optionality: Dx2 (ADHD) data, CE/MDR pathways and broader research partnerships expand addressable market and reduce binary dependence on a single US outcome.

Recommendation: Speculative Buy - 12‑month price target A$1.80 (159% upside). Read the full report for the complete analysis.